Explore
Validate
LearnAM33044PU-S
antibody from Acris Antibodies GmbH
Targeting: CEBPB
C/EBP-beta, CRP2, IL6DBP, LAP, NFIL6, TCF5
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AM33044PU-S - Provider product page
- Provider
- Acris Antibodies GmbH
- Product name
- anti CEBPB (C/EBPB, LAP)
- Antibody type
- Monoclonal
- Antigen
- Recombinant full length mouse C/EBP β protein.
- Reactivity
- Mouse
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- A16
- Vial size
- 25 µg
- Concentration
- 0.5 mg/ml
Submitted references Differential activation of a C/EBP beta isoform by a novel redox switch may confer the lipopolysaccharide-inducible expression of interleukin-6 gene.
Transcriptional induction of the alpha-1 acid glycoprotein (AGP) gene by synergistic interaction of two alternative activator forms of AGP/enhancer-binding protein (C/EBP beta) and NF-kappaB or Nopp140.
Su WC, Chou HY, Chang CJ, Lee YM, Chen WH, Huang KH, Lee MY, Lee SC
The Journal of biological chemistry 2003 Dec 19;278(51):51150-8
The Journal of biological chemistry 2003 Dec 19;278(51):51150-8
Transcriptional induction of the alpha-1 acid glycoprotein (AGP) gene by synergistic interaction of two alternative activator forms of AGP/enhancer-binding protein (C/EBP beta) and NF-kappaB or Nopp140.
Lee YM, Miau LH, Chang CJ, Lee SC
Molecular and cellular biology 1996 Aug;16(8):4257-63
Molecular and cellular biology 1996 Aug;16(8):4257-63
No comments: Submit comment
Supportive validation
- Submitted by
- Acris Antibodies GmbH (provider)
- Main image
- Experimental details
- Nuclear extracts from P388D1 (IL-1) were resolved by electrophoresis, transferred to nitrocellulose and probed with anti-C/EBP Ã (clone A16). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence system. As shown, this antibody specifically recognizes the LAP isoform of C/EBP Ã.
